Probable HTLV-I/II Tropical Spastic Paraparesis Patient from Ethiopia: A Case Report.


Journal

Ethiopian journal of health sciences
ISSN: 2413-7170
Titre abrégé: Ethiop J Health Sci
Pays: Ethiopia
ID NLM: 101224773

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 25 02 2022
accepted: 12 05 2022
entrez: 11 8 2022
pubmed: 12 8 2022
medline: 13 8 2022
Statut: ppublish

Résumé

Available data on the burden of Human T-cell lymphotropic virus type I/II infection for eastern Africa, limited to Ethiopia, Mozambique, and Rwanda, show prevalence lower than elsewhere in Africa (0% - 1.8%). Even if Tropical Spastic Paraparesis occurs in an endemic form in Ethiopia, its seroprevalence is low. Over a lifetime, it is estimated that 1-2% of Human T-cell lymphotropic virus type I/ II -infected individuals will develop progressive and disabling inflammatory clinical manifestations. We are reporting this case since it signifies the existence of seropositive Tropical Spastic Paraparesis in our setting and the need to properly diagnose this condition. We are reporting a 45 years old female patient from Addis Ababa, Ethiopia, who presented with progressive weakness of the lower limbs and urinary urge incontinence of five years duration. Serology for Human T-cell lymphotropic virus type I/ II antibody was positive. She was diagnosed to have probable tropical spastic paraparesis after fulfilling World Health Organization diagnostic criteria for tropical spastic paraparesis with the level of ascertainment. Symptoms showed transient improvements after providing five days of Methylprednisolone followed by low doses of corticosteroids and Azathioprine. The patient is now significantly disabled and wheelchair-bound. The patient described here signifies a probable Human T-cell lymphotropic virus type I/ II - associated myelopathy/tropical spastic paraparesis in Ethiopian women. This case highlights the existence of Human T-cell lymphotropic virus type I/II - associated myelopathy/ tropical spastic paraparesis within our setting and the need to properly diagnose this condition.

Sections du résumé

Background UNASSIGNED
Available data on the burden of Human T-cell lymphotropic virus type I/II infection for eastern Africa, limited to Ethiopia, Mozambique, and Rwanda, show prevalence lower than elsewhere in Africa (0% - 1.8%). Even if Tropical Spastic Paraparesis occurs in an endemic form in Ethiopia, its seroprevalence is low. Over a lifetime, it is estimated that 1-2% of Human T-cell lymphotropic virus type I/ II -infected individuals will develop progressive and disabling inflammatory clinical manifestations. We are reporting this case since it signifies the existence of seropositive Tropical Spastic Paraparesis in our setting and the need to properly diagnose this condition.
Case Presentation UNASSIGNED
We are reporting a 45 years old female patient from Addis Ababa, Ethiopia, who presented with progressive weakness of the lower limbs and urinary urge incontinence of five years duration. Serology for Human T-cell lymphotropic virus type I/ II antibody was positive. She was diagnosed to have probable tropical spastic paraparesis after fulfilling World Health Organization diagnostic criteria for tropical spastic paraparesis with the level of ascertainment. Symptoms showed transient improvements after providing five days of Methylprednisolone followed by low doses of corticosteroids and Azathioprine. The patient is now significantly disabled and wheelchair-bound.
Conclusions UNASSIGNED
The patient described here signifies a probable Human T-cell lymphotropic virus type I/ II - associated myelopathy/tropical spastic paraparesis in Ethiopian women. This case highlights the existence of Human T-cell lymphotropic virus type I/II - associated myelopathy/ tropical spastic paraparesis within our setting and the need to properly diagnose this condition.

Identifiants

pubmed: 35950079
doi: 10.4314/ejhs.v32i4.24
pii: jEJHS.v32.i4.pg865
pmc: PMC9341022
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

865-868

Informations de copyright

© 2022 Dereje Melka, el A. et al.

Références

AIDS Res Hum Retroviruses. 2006 Oct;22(10):931-5
pubmed: 17067261
Neurol Clin. 2008 Aug;26(3):781-97, ix-x
pubmed: 18657726
Trans R Soc Trop Med Hyg. 1991 Jan-Feb;85(1):109-12
pubmed: 2068736
Nat Rev Dis Primers. 2015 Jun 18;1:15012
pubmed: 27188208

Auteurs

Dereje Melka (D)

Department of Neurology, Addis Ababa University School of Medicine, Addis Ababa, Ethiopia.

Mehila Zebenigus (M)

Department of Neurology, Addis Ababa University School of Medicine, Addis Ababa, Ethiopia.
Yehuleshet Neurology specialty Clinic, Addis Ababa, Ethiopia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH